Logo image of XBIO

XENETIC BIOSCIENCES INC (XBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XBIO - US9840156023 - Common Stock

2.17 USD
+0.02 (+0.93%)
Last: 1/5/2026, 1:46:50 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XBIO. XBIO was compared to 530 industry peers in the Biotechnology industry. XBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XBIO has reported negative net income.
XBIO had a negative operating cash flow in the past year.
XBIO had negative earnings in each of the past 5 years.
XBIO had a negative operating cash flow in each of the past 5 years.
XBIO Yearly Net Income VS EBIT VS OCF VS FCFXBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -62.28%, XBIO perfoms like the industry average, outperforming 40.94% of the companies in the same industry.
XBIO has a Return On Equity (-79.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.28%
ROE -79.78%
ROIC N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
XBIO Yearly ROA, ROE, ROICXBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

XBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIO Yearly Profit, Operating, Gross MarginsXBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

XBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XBIO has about the same amount of shares outstanding.
Compared to 5 years ago, XBIO has more shares outstanding
XBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XBIO Yearly Shares OutstandingXBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
XBIO Yearly Total Debt VS Total AssetsXBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

XBIO has an Altman-Z score of -53.05. This is a bad value and indicates that XBIO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -53.05, XBIO is not doing good in the industry: 90.75% of the companies in the same industry are doing better.
XBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -53.05
ROIC/WACCN/A
WACC8.83%
XBIO Yearly LT Debt VS Equity VS FCFXBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

XBIO has a Current Ratio of 4.56. This indicates that XBIO is financially healthy and has no problem in meeting its short term obligations.
XBIO's Current ratio of 4.56 is in line compared to the rest of the industry. XBIO outperforms 52.64% of its industry peers.
A Quick Ratio of 4.56 indicates that XBIO has no problem at all paying its short term obligations.
XBIO has a Quick ratio (4.56) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.56
Quick Ratio 4.56
XBIO Yearly Current Assets VS Current LiabilitesXBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.55% over the past year.
XBIO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.30%.
XBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 162.66% yearly.
EPS 1Y (TTM)6.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.77%
Revenue 1Y (TTM)13.3%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%67.2%

3.2 Future

Based on estimates for the next years, XBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 23.09% on average per year.
The Revenue is expected to grow by 4.35% on average over the next years.
EPS Next Y19.04%
EPS Next 2Y-14.79%
EPS Next 3Y23.09%
EPS Next 5YN/A
Revenue Next Year13.64%
Revenue Next 2Y16.77%
Revenue Next 3Y4.35%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XBIO Yearly Revenue VS EstimatesXBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
XBIO Yearly EPS VS EstimatesXBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIO Price Earnings VS Forward Price EarningsXBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIO Per share dataXBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as XBIO's earnings are expected to grow with 23.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.79%
EPS Next 3Y23.09%

More info and screens

0

5. Dividend

5.1 Amount

XBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XENETIC BIOSCIENCES INC

NASDAQ:XBIO (1/5/2026, 1:46:50 PM)

2.17

+0.02 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-16 2026-03-16/amc
Inst Owners2.83%
Inst Owner Change0%
Ins Owners0.82%
Ins Owner Change0%
Market Cap4.97M
Revenue(TTM)2.86M
Net Income(TTM)-3.16M
Analysts43.33
Price TargetN/A
Short Float %0.33%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)25.09%
Min Revenue beat(2)-9.64%
Max Revenue beat(2)59.82%
Revenue beat(4)2
Avg Revenue beat(4)53.3%
Min Revenue beat(4)-13.19%
Max Revenue beat(4)176.22%
Revenue beat(8)3
Avg Revenue beat(8)24.91%
Revenue beat(12)7
Avg Revenue beat(12)37.86%
Revenue beat(16)11
Avg Revenue beat(16)45.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.74
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-2.57
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS1.25
BVpS1.73
TBVpS1.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.28%
ROE -79.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.56
Quick Ratio 4.56
Altman-Z -53.05
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.77%
EPS Next Y19.04%
EPS Next 2Y-14.79%
EPS Next 3Y23.09%
EPS Next 5YN/A
Revenue 1Y (TTM)13.3%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%67.2%
Revenue Next Year13.64%
Revenue Next 2Y16.77%
Revenue Next 3Y4.35%
Revenue Next 5YN/A
EBIT growth 1Y24.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.16%
EBIT Next 3Y-15.29%
EBIT Next 5YN/A
FCF growth 1Y33.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.22%
OCF growth 3YN/A
OCF growth 5YN/A

XENETIC BIOSCIENCES INC / XBIO FAQ

Can you provide the ChartMill fundamental rating for XENETIC BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to XBIO.


What is the valuation status for XBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to XENETIC BIOSCIENCES INC (XBIO). This can be considered as Overvalued.


How profitable is XENETIC BIOSCIENCES INC (XBIO) stock?

XENETIC BIOSCIENCES INC (XBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for XBIO stock?

The financial health rating of XENETIC BIOSCIENCES INC (XBIO) is 6 / 10.